纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | VASH2 |
Uniprot No | Q86V25 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-355aa |
氨基酸序列 | MTGSAADTHRCPHPKGAKGTRSRSSHARPVSLATSGGSEEEDKDGGVLFHVNKSGFPIDSHTWERMWMHVAKVHPKGGEMVGAIRNAAFLAKPSIPQVPNYRLSMTIPDWLQAIQNYMKTLQYNHTGTQFFEIRKMRPLSGLMETAKEMTRESLPIKCLEAVILGIYLTNGQPSIERFPISFKTYFSGNYFHHVVLGIYCNGRYGSLGMSRRAELMDKPLTFRTLSDLIFDFEDSYKKYLHTVKKVKIGLYVPHEPHSFQPIEWKQLVLNVSKMLRADIRKELEKYARDMRMKILKPASAHSPTQVRSRGKSLSPRRRQASPPRRLGRREKSPALPEKKVADLSTLNEVGYQIRI |
预测分子量 | 56.4 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VASH2重组蛋白的3篇参考文献概述:
1. **文献名称**:*"Vasohibin-2 modulates tumor progression in vitro through regulation of angiogenesis and cellular motility"*
**作者**:Sato Y, et al.
**摘要**:研究利用重组VASH2蛋白验证其调控血管生成的作用,发现其通过抑制微管蛋白去酪氨酸化影响内皮细胞迁移,并促进肿瘤微环境中的血管异常生成。
2. **文献名称**:*"Recombinant human vasohibin-2 inhibits tubulin detyrosination and suppresses cancer metastasis"*
**作者**:Zhang Y, et al.
**摘要**:通过大肠杆菌系统表达纯化重组VASH2蛋白,证实其通过结合微管蛋白抑制去酪氨酸化酶活性,降低癌细胞侵袭能力,为抗转移治疗提供依据。
3. **文献名称**:*"Structural and functional characterization of VASH2/SVBP complex in microtubule dynamics"*
**作者**:Li H, Wang X.
**摘要**:解析重组VASH2与伴侣蛋白SVBP的复合物结构,揭示其通过C端结构域调控微管切割功能的分子机制,为靶向VASH2的抑制剂设计奠定基础。
注:以上文献为示例,实际引用需根据具体数据库(如PubMed、Web of Science)检索结果核对作者及标题信息。若文献不足,建议扩展关键词(如“Vasohibin-2 recombinant expression”)或结合相关信号通路(如TGF-β、HIF-1α)进行关联搜索。
Vasohibin-2 (VASH2) is a member of the vasohibin family, initially identified as a pro-angiogenic factor with distinct roles in vascular biology. Unlike its homolog VASH1. which is primarily associated with anti-angiogenic activity, VASH2 is implicated in promoting angiogenesis and vascular remodeling. It is expressed in various tissues, including endothelial cells, cancer cells, and stem cells, and its dysregulation has been linked to pathological conditions such as tumor progression, metastasis, and ischemic diseases. VASH2 exerts its biological functions through multiple mechanisms, including interaction with small vasohibin-binding protein (SVBP) to form a complex that regulates microtubule dynamics and cell motility. Recent studies also highlight its enzymatic activity as a tubulin carboxypeptidase, removing C-terminal tyrosine residues from α-tubulin to influence cellular processes like mitosis and migration.
Recombinant VASH2 protein is engineered for research and therapeutic applications, typically produced via heterologous expression systems (e.g., *E. coli*, mammalian cells) to ensure proper folding and post-translational modifications. Its production involves cloning the VASH2 gene into expression vectors, followed by purification using affinity chromatography. Recombinant VASH2 serves as a critical tool for studying angiogenesis, tumor microenvironments, and neurodevelopmental pathways. In preclinical models, it has shown potential as a diagnostic marker or therapeutic target in cancers and vascular disorders. However, challenges remain in understanding its dual roles in physiological and pathological contexts, as well as optimizing its stability and delivery for clinical use. Ongoing research continues to unravel its complex interactions within cellular networks, aiming to harness its biological properties for innovative treatments.
×